Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,230 JPY | +0.94% |
|
0.00% | +4.53% |
Jun. 10 | Kissei Pharmaceutical Licenses Linzagolix to JW Pharmaceutical for Korean Market | MT |
Jun. 10 | Kissei Pharmaceutical Co., Ltd. Enters into License Agreement with Jw Pharmaceutical Corporation | CI |
Business Summary
Number of employees: 1,779
Sales per Business
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
83.8
%
| 56,243 | 83.3 % | 63,348 | 83.8 % | +12.63% |
Information Services
11.1
%
| 8,285 | 12.3 % | 8,399 | 11.1 % | +1.38% |
Construction Contracting
4.0
%
| 2,343 | 3.5 % | 3,022 | 4.0 % | +28.98% |
Product
1.1
%
| 621 | 0.9 % | 809 | 1.1 % | +30.27% |
Sales per region
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Japan
100.0
%
| 67,493 | 100.0 % | 75,579 | 100.0 % | +11.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mutsuo Kanzawa
CEO | Chief Executive Officer | 74 | 76-03-31 |
Director of Finance/CFO | 62 | 86-03-31 | |
Yasuo Takehana
PSD | President | 63 | 84-03-31 |
Shinji Kikuchi
CTO | Chief Tech/Sci/R&D Officer | 63 | 88-03-31 |
Suminori Sagara
BRD | Director/Board Member | 65 | 82-03-31 |
Director/Board Member | 65 | 83-03-31 | |
Tetsu Takayama
BRD | Director/Board Member | 62 | 85-03-31 |
Keiji Fukushima
BRD | Director/Board Member | 68 | 79-03-31 |
Yoshio Furihata
BRD | Director/Board Member | 62 | 84-03-31 |
Masaki Morozumi
BRD | Director/Board Member | 68 | 80-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mutsuo Kanzawa
CEO | Chief Executive Officer | 74 | 76-03-31 |
Hiroe Sato
BRD | Director/Board Member | 72 | 75-03-31 |
Masaki Morozumi
BRD | Director/Board Member | 68 | 80-03-31 |
Yoshio Furihata
BRD | Director/Board Member | 62 | 84-03-31 |
Masayuki Isaji
AUD | Comptroller/Controller/Auditor | 69 | 80-03-31 |
Keiji Fukushima
BRD | Director/Board Member | 68 | 79-03-31 |
Tetsu Takayama
BRD | Director/Board Member | 62 | 85-03-31 |
Shinji Kikuchi
CTO | Chief Tech/Sci/R&D Officer | 63 | 88-03-31 |
Minoru Nomura
BRD | Director/Board Member | 77 | 16-05-31 |
Suminori Sagara
BRD | Director/Board Member | 65 | 82-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 49,311,185 | 32,019,861 ( 64.93 %) | 5,105,798 ( 10.35 %) | 64.93 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ALTEOGEN INC. 1.80% | 957,590 | 1.80% | 195,135,488 $ |
CG ONCOLOGY, INC. 5.32% | 3,543,533 | 5.32% | 111,869,337 $ |
5,105,798 | 10.35% | 103,474,460 $ | |
DAIICHI SANKYO CO., LTD. 0.09% | 1,734,000 | 0.09% | 59,546,288 $ |
SHIONOGI & CO., LTD. 0.36% | 1,077,000 | 0.36% | 42,026,166 $ |
2,860,000 | 0.57% | 39,052,528 $ | |
THE HACHIJUNI BANK, LTD. 0.64% | 3,276,402 | 0.64% | 21,376,262 $ |
4,918,000 | 3.79% | 18,557,925 $ | |
SUZUKEN CO., LTD. 0.59% | 461,560 | 0.59% | 14,028,142 $ |
2,000,000 | 0.71% | 13,999,760 $ |
Company contact information
![address Kissei Pharmaceutical Co., Ltd.(4547)](https://cdn.zonebourse.com/static/address/6492249.png)
Sector
Sales per Business
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.53% | 880M | |
+4.86% | 71.18B | |
+30.13% | 9.61B | |
+27.03% | 4.73B | |
-20.42% | 4.53B | |
+17.61% | 3.68B | |
+8.68% | 1.96B | |
-36.05% | 2.03B | |
-38.87% | 1.81B | |
-45.08% | 1.71B |
- Stock Market
- Equities
- 4547 Stock
- Company Kissei Pharmaceutical Co., Ltd.